Phase III Trial Compares 6 vs. 12 Months of HER2-Targeted Therapy in Breast Cancer
A phase III trial is investigating whether 6 months of HER2-targeted therapy is more effective than 12 months for HER2-positive breast cancer patients who achieved a pathologic complete response after neoadjuvant chemotherapy.